Status:
TERMINATED
Physician Assessment of the Clinical Utility of a Patient-Specific 3D Electro-Anatomical Heart Model in VT Ablation
Lead Sponsor:
CardioSolv Ablation Technologies
Conditions:
Ischemic Monomorphic Ventricular Tachycardia
Eligibility:
All Genders
18-85 years
Brief Summary
ACE-VT is a clinical pilot study designed to evaluate the ability of the CardioSolv Software System to generate an output for the physician to review in a timely fashion, consistent with the standard ...
Eligibility Criteria
Inclusion
- Participant meets standard criteria for VT ablation and is scheduled for VT ablation by their cardiologist or electrophysiologist
- 18 to 85 years of age
- VT and ischemic cardiomyopathy
- A pre-procedure MRI with LGE is available (performed within 1 year of procedure, unless an MI has occurred since MRI) with adequate image for analysis
- Participant is able and willing to provide written informed consent
Exclusion
- Contradiction to MRI (except those with MRI compatible pacemaker/ICD/CRT devices implanted or site has approved procedure for MRI of non-compatible devices).
- Participant implanted with an LVAD.
- Enrolled in another non-imaging intervention assignment study that could confound the results of this study.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 6 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04841382
Start Date
June 1 2021
End Date
October 6 2022
Last Update
October 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Upenn
Philadelphia, Pennsylvania, United States, 19104